China
Africa
Explore chapters and articles related to this topic
Asbestos exposure and mesothelioma
Published in Dorsett D. Smith, The Health Effects of Asbestos, 2015
Advances have been made in the treatment of peritoneal mesotheliomas, namely intraperitoneal chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Intraperitoneal chemotherapy, involving the administration of certain chemotherapeutic agents directly to the intraperitoneal cavity, was developed as a novel therapeutic strategy early in the 1950s. Intraperitoneal administration of chemotherapy results in higher intraperitoneal concentrations of the cytotoxic medications, particularly when heated, resulting in minimal systemic exposure compared with intravenous administration, which in turn may increase the efficacy of these agents with a substantial reduction in systemic toxicity. Intraperitoneal chemotherapy was used successfully in peritoneal surface malignancies, including malignant peritoneal mesothelioma, pseudomyxoma peritonei, malignant ascites, sarcomatosis, and peritoneal carcinomatosis from gastrointestinal and ovarian cancers. The advent of cytoreduction with hyperthermic intraperitoneal chemotherapy has dramatically improved survival outcomes, with wide median survival estimates of between 2.5 and 9 years. (Elias D, Goéré D, Dumont F et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50(2):332–40; Raza A, Huang WC, Takabe K. Advances in the management of peritoneal mesothelioma. World J Gastroenterol 2014;20(33):11700–12.)
Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties
Published in Expert Review of Medical Devices, 2018
Kevin M. Lewis, Shelly Ikeme, Tolu Olubunmi, Carl Erik Kuntze
Torres et al. [47] presented research abstract data derived from an observational study and noted that intestinal suture or bowel anastomosis reinforcement with HEMOPATCH might contribute to the reduction of surgical complications such as dehiscence, leaks, and fistula formation. The study included 12 peritoneal carcinomatosis patients who underwent complete cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (CRS-HIPEC using coliseum technique). In all subjects, HEMOPATCH was applied to cover up to 1 cm beyond the 5 colo-colonic, 3 ileorectal, and 4 jejunojejunal mechanical suture lines. Compared to an anastomotic dehiscence rate of 7.5% in series of 305 CRS-HIPEC patients, clinical and radiological examinations revealed no anastomotic leakage or dehiscence in any of the 12 patients treated with HEMOPATCH.